{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T06:40:39Z","timestamp":1768459239267,"version":"3.49.0"},"reference-count":34,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2017,3,9]],"date-time":"2017-03-09T00:00:00Z","timestamp":1489017600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0172996","type":"journal-article","created":{"date-parts":[[2017,3,9]],"date-time":"2017-03-09T18:34:44Z","timestamp":1489084484000},"page":"e0172996","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":23,"title":["Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis"],"prefix":"10.1371","volume":"12","author":[{"given":"Surbhi","family":"Sidana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayur","family":"Narkhede","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Elson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debbie","family":"Hastings","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beth","family":"Faiman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Valent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christy","family":"Samaras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hien K.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitchell R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederic J.","family":"Reu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2017,3,9]]},"reference":[{"key":"ref1","unstructured":"National comprehensive cancer network (NCCN). NCCN clinical practice guidelines in oncology, multiple myeloma (V 3.2016). January 2016. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma.pdf\" xlink:type=\"simple\">https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma.pdf<\/ext-link>."},{"key":"ref2","unstructured":"National comprehensive cancer network (NCCN) clinical practice guidelines. NCCN clinical practice guidelines in oncology, systemic light chain amyloidosis (V1.2016).September 2015 <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/amyloidosis.pdf\" xlink:type=\"simple\">https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/amyloidosis.pdf<\/ext-link>."},{"issue":"6","key":"ref3","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1200\/JCO.2009.23.8220","article-title":"Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis","volume":"28","author":"E Kastritis","year":"2010","journal-title":"J Clin Oncol"},{"issue":"14","key":"ref4","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1200\/JCO.2010.32.2271","article-title":"Amyloidosis: pathogenesis and new therapeutic options","volume":"29","author":"G Merlini","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4","key":"ref5","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood-2011-02-334227","article-title":"Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1\/2 study","volume":"118","author":"DE Reece","year":"2011","journal-title":"Blood"},{"issue":"26","key":"ref6","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"PG Richardson","year":"2003","journal-title":"N Engl J Med"},{"issue":"9","key":"ref7","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"JF San Miguel","year":"2008","journal-title":"N Engl J Med"},{"issue":"11","key":"ref8","first-page":"1498","article-title":"Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study","volume":"91","author":"JL Harousseau","year":"2006","journal-title":"Haematologica"},{"issue":"6","key":"ref9","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/j.1365-2141.2005.05540.x","article-title":"Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma","volume":"129","author":"S Jagannath","year":"2005","journal-title":"Br J Haematol"},{"issue":"19","key":"ref10","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1200\/JCO.2005.04.7779","article-title":"Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib","volume":"24","author":"PG Richardson","year":"2006","journal-title":"J Clin Oncol"},{"issue":"9","key":"ref11","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1007\/s00204-014-1316-5","article-title":"Bortezomib-induced peripheral neurotoxicity: an update","volume":"88","author":"AA Argyriou","year":"2014","journal-title":"Archives of toxicology"},{"issue":"3","key":"ref12","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1053\/j.seminhematol.2012.04.001","article-title":"General aspects and mechanisms of peripheral neuropathy associated with bortezomib in patients with newly diagnosed multiple myeloma","volume":"49","author":"A Broyl","year":"2012","journal-title":"Seminars in hematology"},{"issue":"7","key":"ref13","doi-asserted-by":"crossref","first-page":"940","DOI":"10.4161\/cc.7.7.5625","article-title":"Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: a possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition","volume":"7","author":"MS Poruchynsky","year":"2008","journal-title":"Cell cycle (Georgetown, Tex)"},{"issue":"9","key":"ref14","doi-asserted-by":"crossref","first-page":"3828","DOI":"10.1158\/0008-5472.CAN-04-3684","article-title":"Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341\/bortezomib) cytotoxicity in myeloma cell lines","volume":"65","author":"TH Landowski","year":"2005","journal-title":"Cancer research"},{"issue":"21","key":"ref15","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1200\/JCO.2008.18.3087","article-title":"Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy","volume":"27","author":"PG Richardson","year":"2009","journal-title":"J Clin Oncol"},{"issue":"23","key":"ref16","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1182\/blood-2010-07-294983","article-title":"Efficacy and safety of once-weekly bortezomib in multiple myeloma patients","volume":"116","author":"S Bringhen","year":"2010","journal-title":"Blood"},{"issue":"5","key":"ref17","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study","volume":"12","author":"P Moreau","year":"2011","journal-title":"Lancet Oncol"},{"issue":"12","key":"ref18","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.3324\/haematol.2012.067793","article-title":"Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma","volume":"97","author":"B Arnulf","year":"2012","journal-title":"Haematologica"},{"issue":"2","key":"ref19","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"PA Harris","year":"2009","journal-title":"Journal of biomedical informatics"},{"key":"ref20","unstructured":"Common terminology criteria for adverse events version 4.03. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/About.html\" xlink:type=\"simple\">http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/About.html<\/ext-link>."},{"issue":"1","key":"ref21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/leu.2008.291","article-title":"Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma","volume":"23","author":"RA Kyle","year":"2009","journal-title":"Leukemia"},{"issue":"36","key":"ref22","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"G Palladini","year":"2012","journal-title":"J Clin Oncol"},{"issue":"4","key":"ref23","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.beha.2005.01.024","article-title":"Neurological aspects of multiple myeloma and related disorders","volume":"18","author":"A Dispenzieri","year":"2005","journal-title":"Best practice & research Clinical haematology"},{"issue":"5","key":"ref24","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.7314\/APJCP.2015.16.5.2093","article-title":"Once-weekly subcutaneous administration of bortezomib in patients with multiple myeloma","volume":"16","author":"L Wang","year":"2015","journal-title":"Asian Pacific journal of cancer prevention: APJCP"},{"issue":"4","key":"ref25","doi-asserted-by":"crossref","first-page":"e0123866","DOI":"10.1371\/journal.pone.0123866","article-title":"Subcutaneous bortezomib in multiple myeloma patients induces similar therapeutic response rates as intravenous application but it does not reduce the incidence of peripheral neuropathy","volume":"10","author":"J Minarik","year":"2015","journal-title":"PloS one"},{"issue":"21","key":"ref26","doi-asserted-by":"crossref","first-page":"5382-","DOI":"10.1182\/blood.V122.21.5382.5382","article-title":"Once-Weekly Subcutaneous Bortezomib Plus Oral Cyclophosphamide and Dexamethasone Therapy For Relapsed Or Refractory Multiple Myeloma","volume":"122","author":"Y Imamura","year":"2013","journal-title":"Blood"},{"issue":"24","key":"ref27","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","article-title":"Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/ GMMG-HD4 trial","volume":"30","author":"P Sonneveld","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref28","article-title":"Results from two phase III studies of bortezomib (BTZ) consolidation vs observation (OBS) post-transplant in patients (pts) with newly diagnosed multiple myeloma (NDMM)","author":"C Straka","year":"2015","journal-title":"J Clin Oncol"},{"issue":"24","key":"ref29","doi-asserted-by":"crossref","first-page":"4308","DOI":"10.1002\/cncr.28340","article-title":"Treatment trade-offs in myeloma: A survey of consecutive patients about contemporary maintenance strategies","volume":"119","author":"BL Burnette","year":"2013","journal-title":"Cancer"},{"issue":"9","key":"ref30","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1177\/1060028013503122","article-title":"Subcutaneous versus intravenous bortezomib: efficiency practice variables and patient preferences","volume":"47","author":"MS Barbee","year":"2013","journal-title":"The Annals of pharmacotherapy"},{"issue":"9","key":"ref31","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1182\/blood-2012-04-422683","article-title":"A phase 1\/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma","volume":"120","author":"AJ Jakubowiak","year":"2012","journal-title":"Blood"},{"issue":"17","key":"ref32","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"374","author":"P Moreau","year":"2016","journal-title":"N Engl J Med"},{"issue":"7","key":"ref33","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1182\/blood-2014-01-548941","article-title":"Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed\/refractory multiple myeloma","volume":"124","author":"SK Kumar","year":"2014","journal-title":"Blood"},{"issue":"13","key":"ref34","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S1470-2045(14)71125-8","article-title":"Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1\/2 study","volume":"15","author":"SK Kumar","year":"2014","journal-title":"Lancet Oncol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0172996","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,3]],"date-time":"2020-10-03T17:10:22Z","timestamp":1601745022000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0172996"}},"subtitle":[],"editor":[{"given":"Yves","family":"St-Pierre","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2017,3,9]]},"references-count":34,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,3,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0172996","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,9]]}}}